A
43.20
-1.75 (-3.89%)
| Penutupan Terdahulu | 44.95 |
| Buka | 44.66 |
| Jumlah Dagangan | 452,062 |
| Purata Dagangan (3B) | 508,980 |
| Modal Pasaran | 1,208,433,536 |
| Harga / Jualan (P/S) | 7.93 |
| Harga / Buku (P/B) | 114.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -125.70% |
| Margin Operasi (TTM) | -99.16% |
| EPS Cair (TTM) | -4.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 286.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,016.89% |
| Nisbah Semasa (MRQ) | 8.25 |
| Aliran Tunai Operasi (OCF TTM) | -108.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.04 M |
| Pulangan Atas Aset (ROA TTM) | -15.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -343.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | AnaptysBio, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.40 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.09% |
| % Dimiliki oleh Institusi | 133.99% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 100.00 (Guggenheim, 131.48%) | Beli |
| Median | 55.50 (28.47%) | |
| Rendah | 36.00 (Truist Securities, -16.67%) | Pegang |
| Purata | 62.38 (44.40%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 40.82 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 70.00 (62.04%) | Beli | 45.21 |
| Barclays | 17 Dec 2025 | 55.00 (27.31%) | Beli | 45.69 |
| 11 Nov 2025 | 70.00 (62.04%) | Beli | 33.56 | |
| Stifel | 11 Dec 2025 | 56.00 (29.63%) | Beli | 45.78 |
| 29 Oct 2025 | 80.00 (85.19%) | Beli | 36.12 | |
| HC Wainwright & Co. | 24 Nov 2025 | 51.00 (18.06%) | Beli | 41.95 |
| 11 Nov 2025 | 52.00 (20.37%) | Beli | 33.56 | |
| Wedbush | 24 Nov 2025 | 50.00 (15.74%) | Beli | 41.95 |
| Truist Securities | 10 Nov 2025 | 36.00 (-16.67%) | Pegang | 33.98 |
| Guggenheim | 05 Nov 2025 | 100.00 (131.48%) | Beli | 36.00 |
| Wells Fargo | 05 Nov 2025 | 81.00 (87.50%) | Beli | 36.00 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FAGA DANIEL | - | 44.07 | -38,792 | -1,702,879 |
| LIZZUL PAUL F. | - | 44.07 | -10,104 | -443,175 |
| LOUMEAU ERIC J | - | 44.36 | -14,832 | -661,443 |
| MARQUET MAGDA | - | 46.31 | -11,000 | -509,410 |
| MULROY DENNIS | - | 44.07 | -7,786 | -341,699 |
| Jumlah Keseluruhan Kuantiti Bersih | -82,514 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,658,606 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 44.31 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MARQUET MAGDA | Pengarah | 15 Jan 2026 | Jual (-) | 11,000 | 46.31 | 509,410 |
| MARQUET MAGDA | Pengarah | 15 Jan 2026 | Pelaksanaan pilihan | 11,000 | - | - |
| FAGA DANIEL | Pegawai | 08 Jan 2026 | Jual (-) | 14,281 | 43.80 | 625,508 |
| LOUMEAU ERIC J | Pegawai | 08 Jan 2026 | Jual (-) | 2,210 | 43.80 | 96,798 |
| MULROY DENNIS | Pegawai | 08 Jan 2026 | Jual (-) | 2,515 | 43.80 | 110,157 |
| LIZZUL PAUL F. | Pegawai | 08 Jan 2026 | Jual (-) | 3,650 | 43.80 | 159,870 |
| MULROY DENNIS | Pegawai | 07 Jan 2026 | Jual (-) | 1,908 | 45.21 | 86,261 |
| FAGA DANIEL | Pegawai | 07 Jan 2026 | Jual (-) | 9,202 | 45.21 | 416,022 |
| LIZZUL PAUL F. | Pegawai | 07 Jan 2026 | Jual (-) | 2,235 | 45.21 | 101,044 |
| LOUMEAU ERIC J | Pegawai | 07 Jan 2026 | Jual (-) | 2,017 | 45.21 | 91,189 |
| LOUMEAU ERIC J | Pegawai | 07 Jan 2026 | Jual automatik (-) | 7,622 | 45.21 | 344,591 |
| FAGA DANIEL | Pegawai | 07 Jan 2026 | Pelaksanaan pilihan | 26,838 | - | - |
| LOUMEAU ERIC J | Pegawai | 07 Jan 2026 | Pelaksanaan pilihan | 5,888 | - | - |
| MULROY DENNIS | Pegawai | 07 Jan 2026 | Pelaksanaan pilihan | 6,700 | - | - |
| LIZZUL PAUL F. | Pegawai | 07 Jan 2026 | Pelaksanaan pilihan | 8,525 | - | - |
| MULROY DENNIS | Pegawai | 06 Jan 2026 | Pelaksanaan pilihan | 5,245 | - | - |
| FAGA DANIEL | Pegawai | 06 Jan 2026 | Pelaksanaan pilihan | 17,850 | - | - |
| LIZZUL PAUL F. | Pegawai | 06 Jan 2026 | Pelaksanaan pilihan | 6,145 | - | - |
| LOUMEAU ERIC J | Pegawai | 06 Jan 2026 | Pelaksanaan pilihan | 5,545 | - | - |
| LOUMEAU ERIC J | Pegawai | 05 Jan 2026 | Jual (-) | 2,983 | 43.20 | 128,866 |
| LIZZUL PAUL F. | Pegawai | 05 Jan 2026 | Jual (-) | 4,219 | 43.20 | 182,261 |
| MULROY DENNIS | Pegawai | 05 Jan 2026 | Jual (-) | 3,363 | 43.20 | 145,282 |
| FAGA DANIEL | Pegawai | 05 Jan 2026 | Jual (-) | 15,309 | 43.20 | 661,349 |
| Papar semua | ||||||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |